Does PGT-A Really Raise Your Odds of a Baby?

Does PGT-A actually improve your chance of a baby?

For the average IVF patient, PGT-A has not been shown to raise the overall chance of having a baby. It is a selection tool, not a treatment: it screens the embryos you already made for the correct number of chromosomes and helps decide which to transfer first. That can raise the odds of any single transfer succeeding, because a chromosomally normal embryo implants more reliably. But selecting among your embryos does not add embryos, so across a whole egg retrieval the total live-birth rate tends to be similar whether or not you test.

The most direct evidence comes from a randomized trial in good-prognosis patients, which found that PGT-A did not improve ongoing-pregnancy rates compared with choosing embryos by appearance alone 1Ref 1Munné S, et al. (STAR Study Group) (2019).Preimplantation genetic testing for aneuploidy versus morphology as selection criteria for single frozen-thawed embryo transfer in good-prognosis patients: a multicenter randomized clinical trial.In a randomized trial of good-prognosis patients, PGT-A did not improve ongoing-pregnancy rates per intention-to-treat versus morphology-based selection for single frozen-thawed transfer.. Reviewing the accumulated trials, ASRM and SART conclude that the value of PGT-A as a routine screen for all IVF patients has not been demonstrated, and that recent multicenter trials found similar overall pregnancy outcomes with and without it 2Ref 2Practice Committees of ASRM and SART (2024).The use of preimplantation genetic testing for aneuploidy: a committee opinion.ASRM and SART hold that the value of PGT-A as a routine screen for all IVF patients has not been demonstrated and that recent multicenter RCTs found similar overall pregnancy outcomes with and without it — grounds for framing PGT-A as a discussion rather than a default.. None of this means PGT-A is useless — it means the honest claim is narrower than the marketing, and the benefit, where it exists, is about efficiency and selection rather than a higher ceiling on your chance of a baby.

PGT-A selects among the embryos you already have — it does not add embryos, so it rarely raises the total chance of a baby from a retrieval.

What PGT-A actually tests

PGT-A — preimplantation genetic testing for aneuploidy — checks whether an embryo has the normal number of chromosomes before it is transferred. A few cells are biopsied from the outer layer of a blastocyst, analyzed in a genetics lab, and the embryo is frozen while the result comes back. Embryos with the right chromosome count are called euploid; those with an extra or missing chromosome are aneuploid, the most common reason an embryo fails to implant or ends in early miscarriage.

It is worth being precise about what PGT-A does and does not look at, because preimplantation genetic testing IVF comes in more than one form. PGT-A screens the count of chromosomes; it is not the same as PGT-M single gene disorders testing, which a couple uses when one partner is a known carrier of a specific inherited condition, nor PGT-SR, used for structural chromosome rearrangements. PGT-A does not test for every genetic condition, and it does not measure an embryo's overall 'quality' beyond chromosome number. This page is about whether PGT-A improves success; a fuller explanation of the test itself lives separately.

euploid — an embryo with the normal number of chromosomes; aneuploid means it has an extra or missing chromosome.

The per-transfer versus per-patient gap

The single most important thing to understand about PGT-A statistics is the denominator trap: a number measured per transfer looks very different from the same clinic's number measured per patient or per retrieval. PGT-A almost always improves the per-transfer figure, because you are only transferring embryos that already passed the screen — the aneuploid ones that would likely have failed were set aside first. That is real, but it is arithmetic, not extra babies.

Spread across everyone who started a retrieval, the picture flattens. SART reports IVF outcomes several ways — per intended egg retrieval, per transfer, and per new patient — precisely because these can diverge, and a flattering per-transfer rate can sit alongside an unchanged per-patient rate 3Ref 3Society for Assisted Reproductive Technology (SART) (2024).National Summary Report (SART CORS Online).SART reports IVF outcomes per intended egg retrieval, per transfer, and per new patient, so a flattering per-transfer rate can coexist with an unchanged per-patient rate — the denominator distinction behind PGT-A success claims.. This is why the same test can be advertised as 'boosting success by improving implantation' while the trials show similar overall outcomes: both statements can be true at once, describing different denominators 2Ref 2Practice Committees of ASRM and SART (2024).The use of preimplantation genetic testing for aneuploidy: a committee opinion.ASRM and SART hold that the value of PGT-A as a routine screen for all IVF patients has not been demonstrated and that recent multicenter RCTs found similar overall pregnancy outcomes with and without it — grounds for framing PGT-A as a discussion rather than a default.. When a clinic quotes you a PGT-A success rate, the honest question is 'per what?' A per-transfer improvement tells you little about your chance of a baby from this whole cycle.

What the randomized trials found

When PGT-A is tested head-to-head against choosing embryos by appearance, the added benefit largely disappears for the general population. The STAR trial randomized good-prognosis patients to single frozen-embryo transfer with PGT-A or with standard morphology-based selection and found no improvement in ongoing-pregnancy rates from testing, analyzed by intention to treat 1Ref 1Munné S, et al. (STAR Study Group) (2019).Preimplantation genetic testing for aneuploidy versus morphology as selection criteria for single frozen-thawed embryo transfer in good-prognosis patients: a multicenter randomized clinical trial.In a randomized trial of good-prognosis patients, PGT-A did not improve ongoing-pregnancy rates per intention-to-treat versus morphology-based selection for single frozen-thawed transfer.. Analyzing by intention to treat — counting everyone who was randomized, including those who ended up with no euploid embryo to transfer — is what keeps the comparison honest, because it captures the people PGT-A leaves with nothing to move forward.

Reviewing this and later multicenter trials, ASRM and SART reached a deliberately cautious position: the value of routine PGT-A for all IVF patients has not been demonstrated, and overall pregnancy outcomes were similar with and without it 2Ref 2Practice Committees of ASRM and SART (2024).The use of preimplantation genetic testing for aneuploidy: a committee opinion.ASRM and SART hold that the value of PGT-A as a routine screen for all IVF patients has not been demonstrated and that recent multicenter RCTs found similar overall pregnancy outcomes with and without it — grounds for framing PGT-A as a discussion rather than a default.. Some observational studies and subgroup analyses suggest possible benefit in specific groups, but the randomized evidence — the strongest kind — does not support offering PGT-A to everyone as a way to raise the chance of a baby. That gap between promotional claims and trial results is the core of the honest answer.

Where PGT-A can genuinely help

PGT-A earns its place in narrower situations, mostly by making the path more efficient rather than raising the ceiling. Its clearest use is supporting confident single-embryo transfer: knowing an embryo is euploid makes it easier to transfer just one, which is why guidance on elective single-embryo transfer highlights euploid embryos as strong candidates for moving one at a time while preserving cumulative success and cutting the risk of twins 4Ref 4Practice Committees of ASRM and SART (2021).Guidance on the limits to the number of embryos to transfer: a committee opinion.Elective single-embryo transfer is recommended, with euploid blastocysts as strong candidates for transferring one at a time while preserving cumulative live-birth rates and cutting twin risk — the setting where a euploid PGT-A result is most useful.. For someone weighing whether to transfer one embryo or two, a euploid result can make 'one' the confident choice.

PGT-A can also reduce the number of failed transfers and early miscarriages a person goes through to reach a live birth, and it can shorten the emotional marathon of transferring embryos one by one that were never going to work. For older patients, who make a higher proportion of aneuploid embryos, testing can prevent transfers that were destined to fail — though the trials still do not show it raising the overall live-birth rate. The reasonable framing is that PGT-A may change the route and the number of transfers, and for some people that is worth a great deal, even when it does not change the destination.

What PGT-A costs you: embryos, money, and lab steps

PGT-A is not free of trade-offs, and they are part of the honest calculation. It adds a per-embryo testing fee on top of the cycle, and it commits you to a freeze-all cycle: the embryos are biopsied and frozen while results are pending, then transferred later. That matters because freezing itself is not a shortcut to higher success — a randomized trial in women without PCOS found no live-birth advantage of frozen transfer over fresh — so the freeze-all that PGT-A requires is a consequence of testing, not a bonus 5Ref 5Vuong LN, et al. (2018).IVF Transfer of Fresh or Frozen Embryos in Women without Polycystic Ovaries.A randomized trial in women without PCOS found no live-birth advantage of frozen over fresh transfer, so the freeze-all cycle that PGT-A requires is a consequence of testing rather than an added benefit..

Testing also generally requires ICSI, injecting a single sperm into each egg, so that stray sperm on the outside of the egg do not contaminate the genetic sample; ASRM lists PGT as one of the legitimate reasons to use ICSI even without male-factor infertility 6Ref 6Practice Committees of ASRM and SART (2026).Intracytoplasmic sperm injection for nonmale factor indications: a committee opinion.ASRM lists PGT as a legitimate indication for ICSI even without male-factor infertility, which is why PGT-A cycles generally add ICSI as an extra step and cost.. Each of these is an added cost and an added lab step. The biopsy is a small procedure on the embryo, and some cycles end with no euploid embryo to transfer at all, which is painful information even when it is useful. Whether these trade-offs are worth it depends on your age, embryo numbers, and goals — and on the cost per live birth math, which belongs to the financial conversation rather than this one.

How to read a clinic's PGT-A pitch

Because the honest and the promotional versions of PGT-A rely on different numbers, a few concrete questions cut through most of the confusion at a consult. The first is simply 'per what?' — whether a quoted success rate is measured per transfer, per retrieval, or per patient, since only the last two reflect your chance from a whole cycle 3Ref 3Society for Assisted Reproductive Technology (SART) (2024).National Summary Report (SART CORS Online).SART reports IVF outcomes per intended egg retrieval, per transfer, and per new patient, so a flattering per-transfer rate can coexist with an unchanged per-patient rate — the denominator distinction behind PGT-A success claims.. A per-transfer figure will almost always look impressive for PGT-A and tell you very little about your odds of going home with a baby.

The second question is whether the improvement being described is a live-birth improvement or an implantation-per-transfer improvement, because those are different claims and only the narrower one is well supported. It also helps to ask what happens in the cases PGT-A does not help: how often a cycle ends with no euploid embryo to transfer, and what the plan is then, since that outcome is part of the honest picture. A clinic that presents PGT-A as a routine upgrade for everyone is running ahead of the guidelines, which describe its routine value as unproven and treat it as a discussion rather than a default 2Ref 2Practice Committees of ASRM and SART (2024).The use of preimplantation genetic testing for aneuploidy: a committee opinion.ASRM and SART hold that the value of PGT-A as a routine screen for all IVF patients has not been demonstrated and that recent multicenter RCTs found similar overall pregnancy outcomes with and without it — grounds for framing PGT-A as a discussion rather than a default.. None of this is an argument for refusing the test. It is an argument for pricing it accurately — as a selection and efficiency tool with real trade-offs, not a lever that raises your ceiling — and the clinics worth trusting tend to describe it that way without being asked.

How to decide whether PGT-A is worth it for you

Because PGT-A helps with selection rather than raising your overall odds, the decision is genuinely individual, and 'no' is a legitimate answer. It tends to matter more when you have several embryos to choose among and want to transfer one at a time confidently, or when repeated transfers of untested embryos have failed. It tends to matter less when you have only one or two embryos, since testing cannot improve embryos you do not have and a 'no euploid' result can leave you with nothing to transfer.

The useful questions to bring to a clinic are concrete: how many embryos am I likely to have, what does the per-patient — not per-transfer — evidence say for someone my age, and what happens if testing leaves me with none to move forward? Because the routine benefit is unproven, ASRM frames PGT-A as a discussion to have rather than a default to accept 2Ref 2Practice Committees of ASRM and SART (2024).The use of preimplantation genetic testing for aneuploidy: a committee opinion.ASRM and SART hold that the value of PGT-A as a routine screen for all IVF patients has not been demonstrated and that recent multicenter RCTs found similar overall pregnancy outcomes with and without it — grounds for framing PGT-A as a discussion rather than a default.. A clinic that presents it as essential for everyone is ahead of the evidence. The right choice is the one that fits your embryo numbers, your tolerance for repeated transfers, and your budget — made with clear information rather than a promise.

Declining PGT-A is a reasonable, common choice — it is optional for most patients, not a requirement for a healthy baby.